Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and M...

Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (($MIST)) has held its Q1 earnings call. Read on for the main highlights of the call. Milestone Pharmaceuticals’ latest e...

Milestone Pharmaceuticals’ Earnings Call Highlights Early Launch Momentum

Singapore-based telecom firm Singtel ($SG:Z74) has signed a new deal with Mistral AI, a French private company backed by semiconductor giant ASML H...

Current Quarter	$-0.23	Next Quarter	$-0.21
Current Year	$-0.97	Next Year	$-1.04
QoQ Growth	+8.7%	YoY Growth	-7.2%
3Y EPS CAGR	+18.4%	Target Price	$6.33
Consensus	Buy	Upside	+352.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$1.40	-0.71%	1.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$1.40	-0.7%	1.27M
3
4
5
6

MIST

MIST

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel